Replies to post #21245 on PharmaCyte Biotech Inc (PMCB)

[hispeed]

Sign of the times. But it is a great time to buy on this bailing

[bulldurham]

my thoughts exactly but you already heard...

ThirdPoint Research Releases New Research on SIBE, WTER, and NVLX

According to the American Cancer Society, the rate of pancreatic cancer has been slowly increasing for the past 15 years and by 2030 is expected to be one of the top cancer killers. ThirdPoint’s research outlines the strong position Nuvilex may hold relative to its treatments based on proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box. With demand for new pancreatic cancer treatments skyrocketing and recent FDA approvals in the space, NVLX looks especially well positioned as it prepares to begin late stage clinical trials. Over the coming weeks, ThirdPoint is expecting to expand its research on both WTER and NVLX.

Third Point LLC is an SEC-registered investment adviser based in New York. The firm was founded in 1995 by Daniel S. Loeb, who serves as Chief Executive Officer. Third Point focuses on event-driven, value-oriented investing.

The firm conducts fundamental research to make its investments.
They are a hedge fund with more than 10 Billion under roof....

They are investing in Nuvilex...
bull